Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what discussions his Department has had with (a) the National Institute for Health and Care Excellence and (b) Roche on draft guidance on Kadcyla (trastuzumab emtansine) during the consultation period.
Neither Ministers nor officials have had any such discussions with the National Institute for Health and Care Excellence (NICE). Officials have had contact with Roche about its patient access scheme proposals for trastuzumab emtansine since the consultation on NICE’s draft guidance opened on 20 December 2016.